Wellington Management Group LLP Invests $546,000 in Design Therapeutics, Inc. $DSGN

Wellington Management Group LLP purchased a new stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 141,519 shares of the company's stock, valued at approximately $546,000. Wellington Management Group LLP owned 0.25% of Design Therapeutics as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Palumbo Wealth Management LLC lifted its position in shares of Design Therapeutics by 6.5% in the 1st quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company's stock worth $225,000 after purchasing an additional 3,582 shares during the period. Wells Fargo & Company MN lifted its position in shares of Design Therapeutics by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 18,428 shares of the company's stock worth $114,000 after purchasing an additional 4,013 shares during the period. American Century Companies Inc. lifted its position in shares of Design Therapeutics by 13.5% in the 1st quarter. American Century Companies Inc. now owns 44,415 shares of the company's stock worth $171,000 after purchasing an additional 5,300 shares during the period. Barclays PLC lifted its position in shares of Design Therapeutics by 7.2% in the 4th quarter. Barclays PLC now owns 103,571 shares of the company's stock worth $639,000 after purchasing an additional 6,936 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in shares of Design Therapeutics in the 4th quarter worth about $71,000. Hedge funds and other institutional investors own 56.64% of the company's stock.

Design Therapeutics Stock Up 3.9%

Shares of NASDAQ:DSGN traded up $0.24 on Friday, hitting $6.35. The company had a trading volume of 141,350 shares, compared to its average volume of 135,904. The firm's 50-day simple moving average is $4.48 and its two-hundred day simple moving average is $4.19. Design Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $7.77. The firm has a market capitalization of $361.62 million, a price-to-earnings ratio of -5.67 and a beta of 1.61.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02). Equities research analysts anticipate that Design Therapeutics, Inc. will post -0.91 EPS for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.